38 articles found
Researchers analyze 569,000 TikTok comments to demonstrate social media data can forecast synthetic opioid mortality with 37% greater accuracy than traditional surveillance methods.
New data presented at ASAM 2026 shows extended-release buprenorphine (Sublocade) associated with lowest overdose rates among medication options and supports remission as meaningful treatment endpoint.
State Senator Pat McMath proposes using unspent opioid settlement dollars to fund clinical research into psychedelic-assisted therapy for veterans, first responders, and people with opioid dependence.
UC San Diego and SDSU study of 2.8 million students finds local flavor bans reduce e-cigarette use by 20% with no increase in cigarette smoking, challenging industry arguments.
New research reveals 20% of US pharmacies block access to buprenorphine, with independent pharmacies and southern states showing significantly higher refusal rates for this life-saving opioid addiction medication.
Wake Forest research reveals e-cigarette taxes reduced vaping among heterosexual teens by 3-4 percentage points, yet had no effect on LGBQ youth who use nicotine to cope with bullying and emotional distress.
JAMA research letter reveals 24.3% decline in long-term opioid therapy from 2015-2023, even as co-prescribing with gabapentinoids rises sharply, raising new safety concerns for chronic pain patients.
New ASAM Criteria volume establishes dedicated clinical standards for youth SUD treatment, emphasizing brain development, family engagement, and integrated mental health care
BMJ study of 2.5 million Medicaid births finds children exposed to buprenorphine in utero have no greater risk of ADHD, autism, or other neurodevelopmental disorders compared to methadone exposure.
Flow Neuroscience's transcranial direct current stimulation device becomes first prescription brain stimulation therapy available for home use, offering new option for treatment-resistant depression
New research in Journal of Psychiatric Research reveals individuals with opioid use disorder face 1.88 to 4.17 times greater odds of suicidal thoughts, with moderate cases showing highest attempt rates.
New Anesthesiology research reveals that conventional naloxone doses may not fully reverse respiratory depression from potent synthetic opioids like fentanyl and sufentanil, urging updated emergency protocols
Food and Drug Administration issues complete response letter rejecting Lykos Therapeutics' MDMA-assisted therapy for PTSD, demanding additional clinical trials despite promising efficacy data.
New BMJ research finds semaglutide and similar medications associated with 14% reduced risk of developing substance use disorders and 50% fewer deaths among veterans already in treatment.
World Health Organization updates opioid dependence treatment recommendations, conditionally endorsing monthly injectable buprenorphine formulations as global treatment gap persists.
Northwestern University researchers debunk 2025 drug overdose surge reported by CDC, finding the apparent spike was a modeling error caused by rapid epidemic shifts, not data manipulation or political interference.
Intravenous DMT reduced depressive symptoms within a week in Phase IIa trial, with effects lasting up to three months, according to study published in Nature Medicine.
World Health Organization updates treatment guidelines adding monthly buprenorphine injections to methadone oral medication recommendations addressing epidemic killing three-quarters million people yearly
World Health Organization adds conditional recommendation for monthly and weekly buprenorphine injections, expanding evidence-based options for 61 million people using opioids non-medically worldwide.
New research from Ohio University finds primary care physicians view opioid use disorder as more treatable than diabetes, yet only 8% have ever prescribed buprenorphine, creating treatment deserts in rural America.
World Health Organization adds conditional endorsement for long-acting injectable buprenorphine to global opioid dependence treatment guidelines April 2026, alongside continued strong recommendations for methadone and oral formulations.
University of Pennsylvania researchers develop first brain-targeted gene therapy that mimics morphine's pain relief without triggering reward pathways, offering potential breakthrough for 50 million Americans living with chronic pain.
American Society of Addiction Medicine releases first comprehensive update to youth substance use disorder treatment standards in over a decade, addressing telehealth, trauma-informed care, and medication access.
Kentucky Senate Bill 77 nears final passage, creating framework to research ibogaine for opioid addiction and PTSD despite Schedule I status. Four states already funding trials.
Swedish registry analysis of 100,000 individuals finds GLP-1 medications reduce depression by 44%, anxiety by 38%, and substance use disorders by 47%.
Workit Health's evidence-based virtual care model delivers 62% rural retention at three months—more than double competing programs—with peer-reviewed studies in JAMA Network Open showing perfect buprenorphine adherence among participants.
Brandeis University economic analysis shows two pharmacy-based methadone models generate positive returns of $2.64 and $3.53 per dollar spent over three years while addressing treatment deserts in 80% of U.S. counties.
New research shows patients adherent to extended-release buprenorphine injections had $15,017 lower annual costs and fewer emergency visits than those using other opioid use disorder medications.
VA study of 600,000 patients finds GLP-1 medications like Ozempic reduce substance use disorder risk by 15-20%, suggesting a common biological pathway underlying all addictions.
JAMA Network Open study analyzing Medicare records shows specialists using telemedicine heavily saw only 0.9% more rural patients while treating 3.6% fewer new patients overall.
Federal agency opens funding applications for children's mental health services, suicide prevention frameworks, and assisted outpatient treatment programs as part of broader recovery initiative.
Washington University analysis of 600,000+ VA patients finds GLP-1s tied to 50% reduction in drug-related deaths and lower risk across alcohol, opioid, cocaine, and nicotine use disorders.
Washington University research shows uMAT-R app reduced opioid and drug use by 50% in people experiencing housing insecurity, addressing critical gap in treatment access.
New research identifies myelin remodeling as the missing link between short-term psychedelic experiences and long-term PTSD relief, shifting focus from neurons to oligodendrocytes.
As cocaine and methamphetamine become contaminated with fentanyl, researchers argue that contingency management and culturally adapted harm reduction are essential—yet remain vastly underutilized across the United States.
Imperial College London study published in Nature finds that a single 30-minute DMT session with therapeutic support reduced depressive symptoms more effectively than placebo, marking another step forward for psychedelic-assisted mental health treatment.
New research from Harvard Medical School shows that just 10 yoga sessions can reduce the most severe phase of opioid withdrawal from nine days to five, offering a promising tool for addiction recovery.
Washington University study finds that uMAT-R digital platform reduced substance use by 50% among participants with housing instability, challenging assumptions about technology access in vulnerable populations.